Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410256 ((rac)-N-(3-(1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00100 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410384 (US10377770, Example 144) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410342 (N-(3-((4aR,6R)-6-Hydroxy-1,2,4,4a,5,6-hexahydro-[1...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410350 (US10377770, Example 110) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410277 ((rac)-N-(3-(6-hydroxy-6-methyl-1,2,4,4a,5,6-hexahy...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410352 (US10377770, Example 112) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410356 (US10377770, Example 116 | rac-trans-2-(1,1-Difluor...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410387 (US10377770, Example 147) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00300 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410381 (US10377770, Example 141) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00400 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204382 (US9242996, 461) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00431 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410393 (US10377770, Example 153) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204241 (US9242996, 315) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410357 (2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410362 (US10377770, Example 122 | rac-trans-N-(3-(5-(Hydro...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410351 (US10377770, Example 111) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410358 (2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410363 (US10377770, Example 123 | rac-trans-N-(3-(5-(Hydro...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410231 ((trans)-2-(1,1-difluoroethyl)-N-(3-(6-hydroxy-1,2,...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204384 (US9242996, 463) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00550 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410293 (N-(3-(5,5-bis(hydroxymethyl)-1,2,4,4a,5,6-hexahydr...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410349 (US10377770, Example 109) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410306 (2-(1,1-difluoroethyl)-N-(3-(5-(hydroxymethyl)-1,2,...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410207 ((trans)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro-[1,...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204469 (US9242996, 179) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00612 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204281 (US9242996, 360) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00665 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204470 (US9242996, 180) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00671 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410399 (US10377770, Example 159) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00700 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410223 (US10377770, Example 12) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00700 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410353 (US10377770, Example 113) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410274 ((rac)-(cis)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410268 ((trans)-N-(3-(6-methoxy-1,2,4,4a,5,6-hexahydro-[1,...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410281 (US10377770, Example 43 | US10377770, Example 44) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204316 (US9242996, 395) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00827 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204294 (US9242996, 373) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00837 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204168 (US9242996, 242) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00875 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410269 (US10377770, Example 34) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204405 (US9242996, 478a) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410383 (US10377770, Example 143) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410361 (N-(5-((4aR,5R)-5-(Hydroxymethyl)-1,2,4,4a,5,6-hexa...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410300 ((rac)-N-(3-(5-(hydroxymethyl)-1,2,4,4a,5,6-hexahyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410364 (US10377770, Example 124) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410380 (US10377770, Example 140) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204301 (US9242996, 380) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00970 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204270 (US9242996, 344) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00977 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410359 (US10377770, Example 119 | rac-trans-N-(5-(5-(Hydro...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.0100 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410398 (US10377770, Example 158) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.0100 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410218 (US10377770, Example 11 | US10377770, Example 9) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.0100 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204255 (US9242996, 329) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.0100 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitogen-activated protein kinase 1 (Homo sapiens (Human)) | BDBM204308 (US9242996, 387) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.0100 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Novartis AG US Patent | Assay Description Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept... | US Patent US9242996 (2016) BindingDB Entry DOI: 10.7270/Q2XP73RN | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human)) | BDBM410299 (2-(1,1-difluoroethyl)-N-(4-methyl-3-(2,4,4a,6-tetr...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.0100 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 1629 total ) | Next | Last >> |